Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma.

Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma. Panminerva Med. 2018 Sep;60(3):109-116 Authors: Gupta G, Singhvi G, Chellappan DK, Sharma S, Mishra A, Dahiya R, de Jesus Andreoli Pinto T, Dua K Abstract Glioblastoma, also known as glioblastoma multiforme, is the most common and worldwide-spread cancer that begins within the brain. Glioblastomas represent 15% of brain tumors. The most common length of survival following diagnosis is 12 to 14 months with less than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically 3 months. Among all receptors, special attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in glioblastoma. PPARs are ligand-activated intracellular transcription factors. The PPAR subfamily consists of three subtypes encoded by distinct genes named PPARα, PPARβ/δ, and PPARγ. PPARγ is the most extensively studied subtype of PPAR. There has been interesting preliminary evidence suggesting that diabetic patients receiving PPARγ agonists, a group of anti-diabetics, thiazolidinedione drugs, have an increased median survival for glioblastoma. In this paper, the recent progresses in understanding the potential mechanism of PPARγ in glioblastoma are summarized. PMID: 30176701 [PubMed - in process]
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research